June 4, 2020 -- ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH) and Integrated Biotherapeutics to study molecular binding interactions of therapeutic antibody candidates for COVID-19.
The research consortium will characterize lead antibodies using cyrogenic electron microscopy (cryo-EM) to determine structural details of antibodies bound to the spike protein from SARS-CoV-2. Integrated Biotherapeutics will provide the trimeric spike protein ectodomain and receptor binding domain against which ImmunoPrecise's antibodies will be studied. The data will shed light on how ImmunoPrecise's lead candidate antibodies neutralize the virus.
Copyright © 2020 scienceboard.net